IDH1 and acute myeloid leukemia: Interestingly, Cortes et al. showed the efficacy and the safety of Olutasidenib administered to 18 patients with IDH1-mutant AML who relapsed or were refractory to a Venetoclax regimen; 31.3% of these patients displayed CR + CRi [47].